<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/23/magenta-therapeutics-inc-nasdaqmgta-given-average-rating-of-hold-by-analysts.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-23T22:06:51+00:00"/>
    <meta property="og:title" content="Magenta Therapeutics Inc (NASDAQ:MGTA) Given Average Rating of “Hold” by Analysts"/>
    <meta property="og:description" content="Magenta Therapeutics Inc (NASDAQ:MGTA) has earned a consensus recommendation of “Hold” from the six research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target […]"/>
  </head>
  <body>
    <article>
      <h1>Magenta Therapeutics Inc (NASDAQ:MGTA) Given Average Rating of “Hold” by Analysts</h1>
      <address><time datetime="2019-11-23T22:06:51+00:00">23 Nov 2019, 22:06</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/magenta-therapeutics-inc-logo.jpg"/>
      </figure>
      <p>Magenta Therapeutics Inc (NASDAQ:MGTA) has earned a consensus recommendation of “Hold” from the six research firms that are covering the firm, <a href="https://www.marketbeat.com/">Marketbeat.com</a> reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $19.00.</p>
      <p>A number of equities research analysts recently weighed in on the stock. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> downgraded shares of Magenta Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 15th. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=MGTA">ValuEngine</a> downgraded shares of Magenta Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, Cowen reaffirmed a “buy” rating on shares of Magenta Therapeutics in a research note on Wednesday, November 13th.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/MGTA/price-target/">NASDAQ:MGTA</a> traded up $0.71 on Friday, reaching $13.85. 130,200 shares of the company’s stock were exchanged, compared to its average volume of 87,898. The stock has a fifty day simple moving average of $10.22 and a 200-day simple moving average of $12.41. The firm has a market cap of $512.32 million, a price-to-earnings ratio of -4.42 and a beta of 3.12. Magenta Therapeutics has a 52 week low of $5.31 and a 52 week high of $21.00.</p>
      <p>Magenta Therapeutics (NASDAQ:MGTA) last announced its earnings results on Wednesday, November 13th. The company reported ($0.54) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.54). On average, equities analysts predict that Magenta Therapeutics will post -2.01 EPS for the current fiscal year.</p>
      <p>In other Magenta Therapeutics news, insider Michael P. Cooke sold 5,000 shares of Magenta Therapeutics stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $11.18, for a total transaction of $55,900.00. Insiders have sold 16,656 shares of company stock worth $176,372 over the last three months. Insiders own 10.90% of the company’s stock.</p>
      <p>Several hedge funds have recently bought and sold shares of the business. JPMorgan Chase &amp; Co. raised its stake in shares of Magenta Therapeutics by 52.8% during the second quarter. JPMorgan Chase &amp; Co. now owns 5,349 shares of the company’s stock worth $79,000 after acquiring an additional 1,848 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Magenta Therapeutics by 23.2% during the second quarter. Bank of New York Mellon Corp now owns 52,912 shares of the company’s stock worth $781,000 after acquiring an additional 9,980 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Magenta Therapeutics by 35.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 43,202 shares of the company’s stock worth $638,000 after acquiring an additional 11,205 shares in the last quarter. OneAscent Financial Services LLC purchased a new position in shares of Magenta Therapeutics during the second quarter worth approximately $166,000. Finally, Platinum Investment Management Ltd. raised its stake in shares of Magenta Therapeutics by 7.7% during the second quarter. Platinum Investment Management Ltd. now owns 226,558 shares of the company’s stock worth $3,342,000 after acquiring an additional 16,209 shares in the last quarter. 63.70% of the stock is currently owned by hedge funds and other institutional investors.</p>
      <p>
        <b>Magenta Therapeutics Company Profile</b>
      </p>
      <p>Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/what-is-quick-ratio/">What is the Quick Ratio?</a></p>
    </article>
  </body>
</html>